LRRK2 and cellular pathways of Parkinson's Disease
LRRK2 与帕金森病的细胞通路
基本信息
- 批准号:7125837
- 负责人:
- 金额:$ 18.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-15 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by selective loss of dopaminergic neurons, and the presence of intracellular protein aggregates termed Lewy bodies. The pathogenesis of PD remains incompletely understood, but it appears to involve both genetic susceptibility and environmental factors. Five major genetic causes have been identified, including mutations in alpha-synuclein, parkin, PINK1, DJ-1 and LRRK2, and these mutations have provided models for study of the pathogenesis of genetic PD, with implications for sporadic PD. Mutations in LRRK2 (or dardarin) have been recently identified to cause autosomal dominant late onset, clinically typical PD with pleomorphic pathology. LRRK2 is a large complex protein, and contains domains that suggest roles for protein interactions, kinase activity, and Ras-related signaling. We have extensive experience in studying cell toxicity, signaling pathways, and protein interactions in neurodegenerative diseases. Our previous studies of PD have elucidated the role of alpha-synuclein toxicity, and protein interactions with synphilin-1 and parkin in the formation of Lewy body-like aggregates. We now propose to use similar methods to study LRRK2. We have evidence that LRRK2 interacts with other PD-related gene products and have promising data indicating that mutant LRRK2 can cause direct neuronal toxicity, providing a unique model for studying pathogenesis of LRRK2-related PD. In Specific Aim 1, we will study LRRK2 cellular expression and toxicity, and determine the signaling pathways by which LRRK2 induces neuronal degeneration. We will conduct cell transfection studies using wild type and mutant LRRK2, examine the LRRK2 distribution patterns, and confirm the LRRK2 toxicity. We will generate stable PC12 cell lines which inducibly express either wild type or mutant LRRK2 to study the molecular mechanisms underlying LRRK2 toxicity. In Specific Aim 2, we will test the functional effects of LRRK2 interaction with synphilin-1 and parkin on the pathways of cell toxicity and cellular aggregation using the cell models described in Aim 1. These studies will elucidate the functional role of LRRK2 in cell toxicity and the functional consequences of its interaction with synphilin-1 and parkin in cell culture, will help elucidate the pathogenesis of LRRK2-associated PD, and will identify potential therapeutic targets for intervention in PD.
描述(由申请人提供):帕金森病(PD)是一种进行性神经退行性运动障碍,其特征在于多巴胺能神经元的选择性丧失和称为路易体的细胞内蛋白质聚集体的存在。PD的发病机制仍不完全清楚,但它似乎涉及遗传易感性和环境因素。目前已确定了5种主要的遗传病因,包括α-突触核蛋白、parkin、PINK 1、DJ-1和LRRK 2的突变,这些突变为研究遗传性PD的发病机制提供了模型,并对散发性PD产生了影响。最近已确定LRRK 2(或dardarin)突变可导致常染色体显性迟发性、临床典型PD伴多形性病理。LRRK 2是一个大的复杂蛋白质,包含的结构域表明蛋白质相互作用,激酶活性和Ras相关信号传导的作用。我们在研究神经退行性疾病中的细胞毒性、信号通路和蛋白质相互作用方面拥有丰富的经验。我们以前的PD研究已经阐明了α-突触核蛋白毒性的作用,以及蛋白质与突触亲蛋白-1和parkin的相互作用在形成路易体样聚集体中的作用。我们现在建议使用类似的方法来研究LRRK 2。我们有证据表明LRRK 2与其他PD相关基因产物相互作用,并且有有有希望的数据表明突变型LRRK 2可以引起直接的神经元毒性,为研究LRRK 2相关PD的发病机制提供了独特的模型。在具体目标1中,我们将研究LRRK 2细胞表达和毒性,并确定LRRK 2诱导神经元变性的信号通路。我们将使用野生型和突变型LRRK 2进行细胞转染研究,检查LRRK 2分布模式,并确认LRRK 2毒性。我们将产生可诱导表达野生型或突变型LRRK 2的稳定的PC 12细胞系,以研究LRRK 2毒性的分子机制。在具体目标2中,我们将使用目标1中描述的细胞模型测试LRRK 2与synphilin-1和parkin相互作用对细胞毒性和细胞聚集途径的功能效应。这些研究将阐明LRRK 2在细胞毒性中的功能作用及其与synphilin-1和parkin在细胞培养中相互作用的功能后果,将有助于阐明LRRK 2相关PD的发病机制,并将确定PD干预的潜在治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WANLI W SMITH其他文献
WANLI W SMITH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WANLI W SMITH', 18)}}的其他基金
LRRK2 and cellular pathways of Parkinson's Disease
LRRK2 与帕金森病的细胞通路
- 批准号:
7268124 - 财政年份:2006
- 资助金额:
$ 18.39万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 18.39万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 18.39万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 18.39万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 18.39万 - 项目类别:














{{item.name}}会员




